Fox Run Management, L.L.C. Larimar Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 23,770 shares of LRMR stock, worth $70,596. This represents 0.02% of its overall portfolio holdings.
Number of Shares
23,770
Previous 23,702
0.29%
Holding current value
$70,596
Previous $155,000
41.94%
% of portfolio
0.02%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding LRMR
# of Institutions
125Shares Held
66.8MCall Options Held
500KPut Options Held
61.2K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$63.1 Million2.01% of portfolio
-
Janus Henderson Group PLC London, X06.44MShares$19.1 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$18 Million0.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.65MShares$13.8 Million7.6% of portfolio
-
Goldman Sachs Group Inc New York, NY4.15MShares$12.3 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $129M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...